ReviewInternational journal of molecular sciences2026
Bioactive Constituents and Pharmacological Properties of Lavender Essential Oil: Molecular Mechanisms, Current Evidence, and Future Perspectives.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lavender essential oil (LEO) possesses broad therapeutic potential, yet translating empirical knowledge into evidence-based medicine is hindered by the descriptive literature that conflates isolated monoterpene mechanisms with whole-oil efficacy. Addressing these critical shortcomings, this review presents a target-centric synthesis that explicitly delineates the molecular pathways of pure constituents (e.g., linalool, linalyl acetate) versus intact LEO matrices and standardized oral preparations (Silexan™). We systematically integrate LEO's multi-target signaling networks across neuroregulatory, analgesic, anti-inflammatory, and skin-regenerative domains, while critically examining how genetic taxonomy, environmental stress, and green extraction technologies dictate chemotype diversity. Furthermore, we candidly address current evidence limitations, including pre-clinical predominance, publication bias, and clinical trial narrowness. Finally, we outline actionable translational strategies centered on chemotype-driven standardization, smart delivery systems, and a dual pharmacological paradigm that valorizes non-volatile processing byproducts. This synthesis establishes a rigorous theoretical foundation for LEO's clinical translation and pharmaceutical standardization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.